SaNOtize Research and Development Corp. is a Canadian biotechnology and life sciences startup founded in 2017. The company has created a patented Nitric Oxide Releasing Solution platform technology to address microbial infections, including drug-resistant microbes. Their target indications encompass a wide range of conditions such as strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu, and others.
With antibiotic resistance on the rise globally, SaNOtize's platform technology offers a promising solution to combat resistance and introduce innovative approaches to infection treatment. In August 24, 2022, the company secured a noteworthy $24.00M Series B investment from prominent investors such as OurCrowd, Horizons Ventures, and Agricultural Bank of China. This considerable investment reflects confidence in the potential of SaNOtize's technology and its capacity to revolutionize the fight against infectious diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $24.00M | 3 |
|
24 Aug 2022 |
| Series A | $2.50M | 2 |
|
12 Mar 2020 |
| Angel Round | Unknown | 1 |
|
01 Jan 2018 |
No recent news or press coverage available for SaNOtize Research and Development Corp..
We care about your data, and we'd love to use cookies make your experience better.
